Feiwei Pharmaceutical, a Subsidiary of Totrial, Helps Naishi Medical's Hydrophobic Intraocular Lens Successfully Gain Approval

On September 15, 2023, the monofocal aspherical lightly tinted intraocular lens independently developed by Zhengzhou Naishi Medical Technology Co., Ltd. was registered and approved by the National Medical Products Administration (NMPA). This product is a one-piece foldable posterior chamber type made of a hydrophobic acrylate polymer containing ultraviolet and blue light absorbers. It can replace the human natural lens while protecting the fundus.

As a partner and clinical trial executor, Feiwei Pharmaceutical provided full-process support for the project, including clinical trial management, protocol design, execution, and monitoring, helping the product gain approval successfully. This type of intraocular lens can help patients solve problems such as presbyopia and myopia, allowing them to see clearly without relying on glasses. It significantly improves the vision and quality of life of middle-aged and elderly people, bringing practical value to the field of ophthalmology.